Common Stock, $0.001 par value
- Symbol
- BSEM
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 2.02, 9.01 · 8-K
Item 2.02 Results of Operations and Financial Condition. On August 12, 2026, BioStem Technologies, Inc. (the "Company") issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.…
Press release in this filing
BioStem Technologies Reports Second Quarter 2026 Financial Results →BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.
BioStem Technologies, Inc. · 8-K · Filed 2026-08-12
EX-99.1 2 bsem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioStem Technologies Reports Second Quarter 2026 Financial Results Generates 29% sequential revenue growth, increasing to $7.9 million; Raises full-year 2026 revenue guidance Uplists to Nasdaq Capital Market POMPANO BEACH, FL, August 12, 2026 (GLOBE NEWSWIRE) - BioStem Technologies, Inc. (Nasdaq: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the second quarter ended June 30, 2026. Recent Corporate Highlights • Completed the uplisting of the Company’s common stock to the Nasdaq Capital Market on August 7, 2026 • Completed a $2.5 million private placement with the Company’s first institutional investor Recent Business Highlights • Generated net revenue of $7.9 million for the second quarter of 2026, representing sequential growth of 29% from $6.1 million in the first quarter of 2026 • Continued to scale the commercial organization, expanding the direct sales force, integrating the CRM and ERP systems, and transitioning all major group purchasing organization (GPO) agreement…
Open exhibit ↗